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Wnt signaling is involved in developmental pro-
cesses, cell proliferation, and cell migration. Secreted
frizzled-related protein 4 (sFRP4) has been demon-
strated to be a Wnt antagonist; however, its effects on
endothelial cell migration and angiogenesis have not
yet been reported. Using various in vitro assays, we
show that sFRP4 inhibits endothelial cell migration
and the development of sprouts and pseudopodia as
well as disrupts the stability of endothelial rings in
addition to inhibiting proliferation. sFRP4 interfered
with endothelial cell functions by antagonizing the
canonical Wnt/-catenin signaling pathway and the
Wnt/planar cell polarity pathway. Furthermore, sFRP4
blocked the effect of vascular endothelial growth fac-
tor on endothelial cells. sFRP4 also selectively in-
duced apoptotic events in endothelial cells by increas-
ing cellular levels of reactive oxygen species. In vivo
assays demonstrated a reduction in vascularity after
sFRP4 treatment. Most importantly, sFRP4 restricted
tumor growth in mice by interfering with endothelial
cell function. The data demonstrate sFRP4 to be a
potent angiogenesis inhibitor that warrants further
investigation as a therapeutic agent in the control of
angiogenesis-associated pathology. (Am J Pathol 2010,
176:1505–1516; DOI: 10.2353/ajpath.2010.090465)
Wnt signaling pathways have been implicated in the pro-
liferation, survival, differentiation, and migration of various
cell types,1–4 including endothelial cells.5,6 Furthermore,
Wnt plays an important role in the development of the
vasculature under different conditions, including embry-
onic angiogenesis,7,8 and is known to exert its effect by
modulating both cellular and transcriptional events.9,10
The Wnt proteins are a diverse family of secreted gly-
coproteins that transduce cellular signals by binding to
two coreceptor molecules: the transmembrane frizzled
receptors and lipoprotein receptor-related proteins 5 or
6.7 There are three Wnt signaling pathways: (i) the ca-
nonical, or Wnt-–catenin pathway, which targets a key
cellular regulatory molecule -catenin; (ii) the Wnt-Calcium-
mediated pathway, which mobilizes intracellular calcium
to activate calcium/calmodulin-dependant protein kinase
II and protein kinase C; and (iii) the Wnt-planar cell po-
larity pathway, which signals through Rho-associated ki-
nase and c-Jun–N-terminal kinase.11
Secreted frizzled-related protein 4 (sFRP4) is a mem-
ber of the secreted frizzled-related protein family of Wnt
inhibitors that bind directly to Wnt and antagonize both
canonical and noncanonical Wnt pathways.12 We have
previously shown antiproliferative and proapoptotic
roles for sFRP4 during normal homeostasis in tissues
such as ovary, corpus luteum, placenta, and mammary
gland13–16 but, surprisingly, in pathological states such
as mesothelioma17 and colorectal carcinoma,18 sFRP4
did not induce apoptosis of tumor cells.
The exact mechanisms by which Wnt affects angio-
genesi remains poorly understood; however, Wnt signal-
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ing and the requirements of the canonical Wnt pathway
appear to be essential in endothelial cell (EC) commit-
ment developing from embryonic stem cells.19 Further-
more, coexpression of Wnt proteins and Wnt pathway
inhibitors by endothelial cells is implicated in the regula-
tion of angiogenesis.20,21
To date there are no published data demonstrating the
involvement of sFRP4 in angiogenesis. We report our
investigations on the role of sFRP4 on EC physiology
using a variety of in vitro assays and its effect on physi-
ological and tumor-associated angiogenesis using in vivo
models.
Materials and Methods
Cell Lines and Culture Media
ECV-304 cells were a donation from V. Shah, GI Re-
search Unit, Mayo Clinic, Rochester, MN; Li EA.hy926
cells were donated by C. Edgel, Tissue Culture Facility,
UNC Lineburger Comprehensive Cancer Center, Univer-
sity of North Carolina, Chapel Hill; porcine aortic endo-
thelial cells (PAECs) were donated by R. Rieben, University
of Bern, Switzerland. Human umbilical vein endothelial
cells (HUVECs) were a donation from Dr Chooi-May Lai,
Lions Eye Institute, The University of Western Australia.
All experiments were performed using EA.hy926 cells,
but crucial experiments were repeated in HUVECs and
representative experiments are shown whenever possi-
ble. However, results were comparable with all cell lines
used. Dulbecco’s modified Eagle’s medium (DMEM) was
purchased from Hi-Media, Mumbai, India. Fetal bovine
serum was supplied by Invitrogen Life technologies. Anti–
-catenin antibodies were purchased from Millipore.
Matrigel was obtained from BD Biosciences, San Jose, CA.
Polyether-polyurethane foam sponge was obtained from
Amersham Biosciences (SF) Corp., Piscataway, NJ. All
other chemicals were of reagent grade and were obtained
commercially. For cell culture, cells were maintained in
DMEM supplemented with 10% FBS (v/v), 1% penicillin
(w/v) and streptomycin (w/v) at 37°C/5% CO2. sFRP4 was
supplied by Upstate (Lake Placid, NY).
Animals
Experiments using Wistar rats were conducted with the
approval of the Animal Ethics Committee of Anna Univer-
sity, Chennai, India. Homozygous female BALB/c nu/nu
athymic mice experiments were conducted with approval
from The University of Western Australia Animal Ethics
Committee.
In Vitro Studies
Endothelial Wound Scratch Assay
Primary PAECs and 2 immortalized cell lines (ECV-304
and EA.hy926) were cultured in 24-well plates coated in
collagen type 2 at 2  105 cells per well to produce
confluent monolayers. The monolayers were wounded in
a line using a standard 100-l pipette tip and washed
with PBS (pH 7.4) to remove cell debris before incubation
with different concentrations of sFRP4 (125 and 250 pg/
ml). The area of the cell-free wound at selected time
points (0 and 8 hours) was recorded using a Nikon digital
camera and analyzed using Image J image analysis soft-
ware (Release  4.0 3.2). The wound healing effect was
calculated as the percentage of remaining cell-free area
(at 8 hours) compared with the initial wound area. The
reversibility of the sFRP4-mediated effect was studied by
washing the cells with PBS 24 hours post treatment.
Endothelial Cell Chemotactic Assay
Migration in endothelial cells was examined using a
Boyden chamber migration assay. Collagen-treated poly-
carbonate membranes (pore size 8 m) were used for
the assay. HUVECs were pre-treated with different con-
centrations of sFRP4 (0 and 125 pg/ml) for 2 hours and
trypsinized; 1  105 cells were loaded in the upper
chamber of the Boyden apparatus with or without sFRP4.
After 4 hours of incubation at 37°C and 5%CO2, the
nonmigrated cells of the upper chamber were removed
using a cotton swab. The migrated cells on the underside
were fixed with 4% paraformaldehyde in PBS (pH 7.4)
and stained with propidium iodide (1 g/ml). The mi-
grated cells were counted at 20 magnification using a
fluorescent microscope (Olympus IX71).
Endothelial Ring Formation
HUVECs were seeded on collagen-coated 12-well
plates (1  105 cells per well). After 4 hours of incubation
at 37°C/5%CO2, the media was changed to medium sup-
plemented with sFRP4 (0 or 125 pg/ml). The cells were
incubated with sFRP4 overnight (12 hours) at 37°C/
5%CO2. The endothelial cells formed ring-like structures
on overnight incubation. The number of rings formed was
counted at 20 magnification using a brightfield phase
contrast microscope.
Stability Studies of Ring Structures
HUVECs were seeded as above (1  105 cell per well),
but on coverslips coated with collagen type 2 in 12-well
plates and incubated for 12 hours at 37°C/5%CO2. The
endothelial cells formed ring-like structures on overnight
incubation. Each coverslip was mounted on a custom-
ized live cell chamber and placed on the microscope
stage. Single ring structures were identified and the mi-
croscope stage was fixed in place, after which the cells
were monitored for up to 15 minutes with or without
sFRP4 treatment (125 pg/ml). Images were taken at var-
ious time points.
Effect of Vascular Endothelial Growth Factor on
sFRP4 Action
EA.hy926 cells (which express the vascular endothelial
growth factor [VEGF] receptor) were grown to confluence
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as per the wound scratch protocol. After wounding, cells
were incubated with either VEGF (20 nmol/L), Avastin
(125 pg/ml), sFRP4 (125 pg/ml), a combination of VEGF
and Avastin, or VEGF and sFRP4 for 12 hours. The
amount of wound healing was recorded as previously
described.
Functional Analysis of the Mechanism of sFRP4
Action in Vitro
Wound Healing under the Influence of LiCl
HUVECs were grown to confluence as per wound
scratch assay. After wounding, they were washed with
PBS (pH 7.4) to remove cell debris before incubation
using the GSK-3 inhibitor, LiCl (500 mol/L; Sigma, St
Louis, MO), alone or in combination with sFRP4 (125
pg/ml) for 4 hours. The amount of cell migration was
recorded as previously described.
Proliferation Assay
The proliferation assay was performed as previously
reported.22 In summary, HUVECs were seeded at a den-
sity of 3000 cells per well in 96 wells and incubated
overnight at 37°C/5% CO2, and the following day the cells
were treated with sFRP4 (125 pg/ml) in the presence and
absence of LiCl (500 mol/L). The cells were further
incubated for 48 hours at 37°C/5%CO2. After incubation
the cells were trypsinized and counted in a hemocytom-
eter (Nebauer Improved, Crown Scientific).
Determination of Intracellular Calcium
Calcium levels were determined as previously re-
ported.23 Briefly, intracellular calcium was monitored in
HUVECs using the fluorescent indicator Fura-2 ace-
toxymethyl ester (Fura-2, 1 mol/L, Molecular Probes).
Fluorescence at 340/380 nm excitation and 510 nm emis-
sion wavelengths were measured at 1-minute intervals
with an exposure of 50 milliseconds on a Hamamatsu
Orca ER digital camera attached to an inverted Nikon
TE2000-U microscope. Ratiometric 340/380-nm signal of
individual HUVECs was quantified using Metamorph 6.3
to measure signal intensity of manually traced cell re-
gions. An equivalent region not containing cells was used
for background and was subtracted. Ratiometric 340/
380-nm fluorescence was plotted relative to the pretreat-
ment fluorescence and assigned a value of 1.0. Fluores-
cent ratios recorded for 3 minutes at 37°C just before and
the last 3 minutes of a 10-minute exposure to 125 pg/ml
sFRP4 were averaged, and increases in fluorescent ra-
tios were reported as a percentage increase from the
baseline average. After 10 minutes exposure to 125 pg/
ml, a further 125 pg/ml of sFRP4 was added to create a
final dose of 250 pg/ml, and the change in fluorescence
was monitored as per the 125 pg/ml dose.
Immunoblotting
Whole cell lysates and Western blot analysis were
performed as previously described with minor modifica-
tions.14 Briefly, HUVECs at 70% confluence were stimu-
lated with LiCl (500 mol/L; Sigma, St Louis, MO) in
DMEM for 30 minutes at 37°C and then sFRP4 (125
pg/ml) or PBS was added and cells incubated for a
further 4 hours at 37°C before being harvested for pro-
tein. Lysates were prepared by scraping cells in radio-
immunoprecipitation assay buffer (150 mmol/L NaCl, 50
mmol/L Tris-HCl pH7.5, 1% triton X100, 0.5% sodium
deoxycholate, 0.1% SDS and 0.1 mmol/L PMSF) on ice.
The protein content of the lysates was normalized after
quantification by Bradford protein estimation.24 The ly-
sates were boiled in Laemmli buffer for 5 minutes at 90°C
before loading onto 10% SDS-PAGE gel. After electro-
phoresis the proteins were transferred onto a nitrocellu-
lose membrane using wet blotting apparatus (Biorad).
The membranes were blocked using 5% nonfat milk in
Tris-Buffered Saline Tween-20 (TBST) and probed for
-catenin using anti–-catenin antibody at 1:1000 dilution
in TBST (Cell Signaling) and horse radish peroxidase
(HRP)-labeled secondary antibody at a dilution of
1:10,000 in TBST (Pierce). The blots were developed
using SuperSignal West Pico Chemiluminescent Sub-
strate (Pierce). -actin antibody was used at a concen-
tration of 1:5000 (Sigma). The secondary antibody was
anti-mouse HRP used at 1:10,000 dilution (Pierce).
Isolation of nuclear fragments was performed as pre-
viously reported.25 HUVECs were harvested in incubation
medium and spun down at 500g for 10 minutes at 4°C,
resuspended in PBS, and spun down again using the
same conditions. For isolation of nuclei, cell pellets were
resuspended in 500 l of nuclei isolation buffer (10
mmol/L PIPES, 10 mmol/L KCl, 2 mmol/L MgCl2, 1 mmol/L
DTT, 0.1% protease-inhibitor cocktail, pH 7.4). Cells were
homogenized using a glass potter, layered over 500 l of
30% sucrose in nuclei isolation buffer, and centrifuged for
10 minutes at 800g and 4°C. The pellet was washed with
nuclei isolation buffer and nuclei were lysed with nuclei
isolation buffer containing 0.1% SDS for 30 minutes on
ice. Cellular debris was spun down and the supernatant
stored at 80°C. C-Jun antibody was used at a dilution of
1:1000 in TBST (Cell Signaling) and HRP-labeled sec-
ondary antibody at a dilution of 1:10000 in TBST (Pierce).
The blots were developed as above, and protein content
was quantified using the Bradford assay.
Determination of Levels of H2O2 in EA.hy926
EA.hy926 cells were grown overnight (12 hours) in
tissue culture dishes to attain 60% confluence, then
washed once with PBS and media changed to that sup-
plemented with different concentrations of sFRP4 (0 or
125 pg/ml). The cells were incubated for 4 hours at
37°C/5%CO2, then the medium was aspirated and cells
were washed with PBS (2 times). Cells were incubated in
PBS supplemented with 10 mol/L Amplex Red in the
presence of 0.5U HRP for 15 minutes at 37°C/5%CO2.
The cells were scraped and centrifuged at 2000g at 4°C
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and the supernatant was collected. Fluorometric read-
ings using a Cary eclipse fluorometer (Varian, CA) were
recorded at 563-nm excitation and 587-nm emission
wavelength; the slit width was kept at 5 nm.
Determination of Levels of Superoxides in EA.hy926
Cells
EA.hy926 cells were grown overnight (12 hours) in
12-well plates coated in collagen type 2 (1  106 cells
per well). The next morning cells were washed with PBS
and the media changed to medium supplemented with
sFRP4 (0 or 125 pg/ml). Cells were incubated for 4 hours
at 37°C/5%CO2, following which 1 mg/ml nitroblue tetra-
zolium was added to the media and cells incubated for a
further 2 hours. After incubation the medium was aspi-
rated and cells were washed with PBS (2 times).
Formazan crystals formed by the action of superoxides
on nitroblue tetrazolium were dissolved by adding 200 l
of DMSO and the optical density was measured at 540
nm using a spectrophotometer (Varian Cary 4000 uv-vis
photometer, Varian, CA).
Catalase Activity Assay
EA.hy926 cells were grown overnight (12 hours) in
tissue culture plates coated in collagen type 2 to attain
80% confluence, and the following morning cells were
washed with PBS and the media changed to medium
supplemented with sFRP4 (0 or 125 pg/ml). Cells were
incubated for 4 hours in sFRP4 supplemented medium at
37°C/5%CO2. After incubation, cells were washed 2
times with PBS, scraped in ice cold PBS (500 l/35 mm
dish), and centrifuged to form a pellet at 2000g/4°C.
Supernatant was discarded and the pellet was resus-
pended in 200 l 50 mmol/L Tris-HCl buffer (pH 7.4).
Cells were homogenized on ice using a Dounce homog-
enizer at 50 strokes. The sample was prepared by dilut-
ing lysate in 2 ml 0.1 mol/L PBS buffer (pH 7.4) and 0.1%
H2O2 was added, after which the optical density was
measured at 15-second intervals up to 3 minutes. The
decrease in optical density corresponds to the break-
down of hydrogen peroxide by catalase activity. The
activity of the enzyme was plotted as a function of time
and expressed as the amount of H2O2 consumed/min/mg
of protein.
Investigation of the Influence of Superoxide
Dismutase on sFRP4 Wound Healing Effects
EA.hy926 cells were grown to confluence in 24-well
plates as described in the wound healing assay. A wound
was created as per the wound healing assay and then
incubated with either superoxide dismutase (SOD) or
nothing to determine whether SOD per se had any impact
on wound healing. Next, cells were again grown to con-
fluence and subjected to wounding followed by incuba-
tion with either sFRP4 (125 pg/ml) or sFRP4 (125 pg/ml) in
combination with SOD (150 SI units). Wound healing was
measured for the next 4 hours by taking images of the
wound at 0 and 4 hours of incubation.
In Vivo Studies
Chicken Chorioallantoic Membrane Assay
Fourth day incubated chicken eggs were collected
from the Poultry Research Station, Nandanam, Chennai.
In a modification of the chicken chorioallantoic mem-
brane assay,26 the eggs were broken and gently plated
on a cellophane bed in Petri dishes under sterile condi-
tions. Sterile filter paper disks soaked in sFRP4 (0 or 125
pg/ml) were then placed on the egg yolks and incubated
for another 12 hours at 37°C. Images were taken using a
Nikon digital camera with a stereo microscope at 0, 6,
and 12 hours of incubation. Quantification of angiogene-
sis was performed by using Image J image analysis
software (Release  4.0 3.2).
Cotton Plug Method
Ten to 20 mg of sterile absorbent cotton plugs were
implanted in the peritoneal cavity of Wistar rats with or
without sFRP4 (125 pg/ml). After 8 days the animals were
sacrificed and the cotton plug granulomas were ex-
tracted to measure the hemoglobin content.
Matrigel Sponge Assay
A polyether-polyurethane sponge (0.5 cm2) was
soaked in Matrigel that had been thawed at 4°C and the
sponge was implanted in the peritoneal cavity of Wistar
rats with or without sFRP4 (125 pg/ml). The animals were
sacrificed after eight days, and the resulting granulomas
were removed to measure the hemoglobin levels.
Matrigel Plug Assay
Matrigel (20 mg/ml) was injected into the peritoneal
cavity of Wistar rats with or without sFRP4 (125 pg/ml).
The animals were sacrificed after 8 days to extract the
matrigel pellet. The hemoglobin content of the pellet was
measured spectrophotometrically.
Image Analysis of Implants
Images of the implants were converted to gray scale
and adjusted to suitable brightness and contrast using
Adobe Photoshop 7.0 to perform automated image anal-
ysis using AngioQuant.27 Next, the images were pro-
cessed with AngioQuant software as directed by the
software tools. The number of junctions (which reflects
the number of vessels formed in the implants) was taken
as an index of angiogenesis.
Mouse Tumor Models
BALB/c nude mice were injected subcutaneously with
5  106 SKOV-3 cells, a human cell line derived from
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ovarian serous cystadenocarcinoma. On day 5, when
tumors had grown to 70 to 100 mm3, 100 g of Avastin or
sFRP4 in 100 l PBS, or 100 l PBS alone were injected
intraperitoneally twice weekly for 3 weeks. On day 43 the
tumors were excised under general anesthesia and
immersed in a solution of 4% paraformaldehyde in
phosphate buffer (pH 7.2) and processed for paraffin
embedding. Five-m sections were made for routine
hematoxylin and eosin staining followed by micro-
scopic examination and photography.
Immunohistochemistry
Cryostat sections of frozen tissue were cut at 6 m,
placed on Super Frost Plus slides, and stored at 20°C
until use. Immediately before commencing immunostain-
ing, the sections were washed in PBS buffer for 2 minutes
before incubation with 3% H2O2 (in methanol) for 25
minutes at room temperature to block endogenous per-
oxide activity before 3% bovine serum albumin in PBS for
60 minutes at room temperature to block nonspecific
binding. Sections were stained using Mec 13.3 antibody
(rat anti-mouse CD-31) at a 1:100 dilution (BD Pharmin-
gen, San Diego, CA) overnight at 4°C and then washed in
PBS buffer (2  2 minutes) at room temperature. The
secondary biotinylated antibody (anti-rat) was applied at
a 1:500 dilution (Universal secondary, Vector Laborato-
ries Inc., Burlingame, CA) for 90 minutes at room temper-
ature, followed by 2  2 minute washes in PBS. The ABC
kit (Vectastain Elite ABC, Vector Laboratories Inc., Bur-
lingame, CA) was added for 60 minutes, again followed
by 2  2 minute PBS washes. Diaminobenzidine (Sigma,
Australia) was used as a chromogen to visualize the
antibody–antigen complex. Sections were counterstained
in Harris’s hematoxylin for 45 seconds, dehydrated,
cleared, and mounted in DPX. Slides were examined
using an Olympus BX50 with MicroFire (Optronics) mi-
croscope connected to a Micro Brightfield MBF camera
and using Stereo Investigator software; endothelial cells
were counted at 40 magnification by random sampling
of 8 sites, each site being 150 m  150 m in size.




Cell death was localized in tissue by TUNEL analy-
sis.28 Paraffin sections were cut (4 m) using a mic-
rotome and then dewaxed by two washes in toluene (5
minutes). Sections were hydrated through a graded se-
ries of ethanol and PBS and then incubated with protein-
ase K (20 g/ml in PBS) for 30 minutes at 37°C. There-
after an in situ apoptosis kit (Apoptosis Detection kit,
Chemicon International, Temecula, CA) was used for
nick-end labeling according to the manufacturer’s proto-
col. Nuclei with DNA cleavage were visualized with DAB
(3,3-diaminobenzidine tetrahydrochloride), and sections
were counterstained with methyl green. Postweaning
mammary gland was used as a positive control. Labeling
was visualized indirectly with peroxidase-labeled anti-
digoxigenin antibody. Sections that were near the maxi-
mal diameter of the tumor were selected for investigation.
Slides were examined using an Olympus BX50 with Mi-
croFire (Optronics) microscope connected to a Micro
Brightfield MBF camera and, using Stereo Investigator
software, both normal and apoptotic endothelial cells
were counted at 40 magnification by random sampling
of 8 sites, each site being 150 m  150 m in size.
Counts were performed for PBS, sFRP4, and Avastin
treatment groups.
JC-1 Assay
Initiation of apoptosis was determined using the
JC-1 technique.29 At the onset of apoptosis the mito-
chondrial membrane is rapidly depolarized. When the
mitochondrial membrane is polarized the JC-1 dye
(5,5,6,6-tetrachloro-1,1,3,3-tetraethyl-benzimidazolyl-
carbocyanine iodide) aggregates and fluoresces red. On
depolarization, JC-1 forms a green fluorescent monomer,
so the ratio of aggregated to monomeric JC-1 gives a
quantitative representation of the extent of mitochondrial
membrane permeability. Apoptotic cells primarily dem-
onstrate green fluorescence, whereas healthy cell fluo-
resce red/green. Briefly, cells were grown at 1  105 c/ml
in 96-well plates for 24 hours. After either 1 or 3 hours of
1 mol/L STS treatment, media was removed and 50 l of
2.5 mmol/L JC-1 (Molecular Probes T-3168) dye diluted
1:75 in Hams F12-K was added and incubated for 60
minutes. Positive controls were conducted by the addi-
tion of 50 mol/L FCCP (carbonyl cyanide p-[trifluorome-
thoxy] phenylhydrazone). JC-1 was removed and cells
washed with 5% bovine serum albumin in PBS. Plates
were analyzed using a FluoStar fluorescent plate reader.
The green monomeric form has absorption/emission
maxima of 510/527 nm while the aggregate (red) form
has absorption/emission maxima of 585/590 nm.30 Raw
values at 590 nm were divided by the raw values of the
corresponding well at 520 nm.
Statistical Analyses
Data are presented as mean  SEM. n for each experi-
ment is indicated in figure legends and refers to the
number of well replicates per group. Analysis of variance
was used to assess variation between control and treat-
ment groups. For comparisons in which F test for the
analysis of variance reached statistical significance (P 




We used a wound scratch assay using two concentra-
tions of sFRP4 (125pg/ml and 250pg/ml) on three differ-
ent endothelial cell lines; primary PAECs and the immor-
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talized human EC lines, ECV-304 and EA.hy926. In all
three cell types, sFRP4 induced a significant reduction
(P  0.05) in EC migration (Figure 1A). Treatment with
250 pg/ml and 125 pg/ml were equally effective in inhib-
iting wound healing (Figure 1A), thus the 125 pg/ml dose
was used in subsequent studies. Inhibitory effects of
sFRP4 on PAEC migration were maintained up to 24
hours after treatment as indicated in the time course
results (Figure 1B). However, this inhibition was abol-
ished within three hours of washing for the 125 pg/ml
dose. The duration of these inhibitory effects on EC mi-
gration healing suggest that sFRP4 exerts its effect by
inhibiting both proliferation and migration of endothelial
cells.
Chemotactic migration of endothelial cells is a key
event in angiogenesis, and we investigated the effect of
sFRP4 on EC migration using a Boyden’s chamber mi-
gration assay and HUVECs. EC migration was signifi-
cantly reduced (P  0.01) after sFRP4 treatment of 125
pg/ml (Figure 1C).
Endothelial cell ring formation and ring stability also
were examined using HUVECs. sFRP4 administration in-
duced a significant reduction in numbers of endothelial
rings formed (P  0.01; Figure 1D) and a reduction of
pseudopodia, together with a loss of stability of ring
structures within 30 minutes of sFRP4 treatment (Figure
1E). Together these results demonstrate inhibition of en-
dothelial cell spreading, development of pseudopodia,
and sprout formation, all of which are important in the
initiation and development of angiogenesis.
The interaction between sFRP4 and VEGF was also
examined using the wound scratch assay. Addition of
VEGF to EA.hy926 cells (which express the VEGF recep-
tor) predictably increased the percentage of wound heal-
ing (P  0.01), whereas addition of the VEGF receptor
blocker Avastin restored wound healing activity to control
levels. sFRP4, both in the presence or absence of VEGF,
significantly reduced (P  0.01) wound healing (Figure
1F) to a greater extent than observed for Avastin (P 
0.01). Thus, exogenous VEGF is unable to block the
effects of sFRP4 on cell migration.
Functional Analysis of sFRP4-Wnt Signaling
Pathway Interaction in Vitro
Our in vitro data demonstrated a significant effect of
sFRP4 on migration; therefore, we examined the expres-
Figure 1. Effect of sFRP4 on wound scratch
assay. A: A slower movement of ECs in compar-
ison with that of control was recorded under
both 125 and 250 pg/ml sFRP4 treatments (*125
pg/ml P  0.05; *250 pg/ml P  0.05, n  3). B:
Withdrawing sFRP4 treatment of PAECs by
washing recovered wound healing effects (*125
pg/ml P  0.05, n  3) after 6 hours. C: sFRP4
blocked migration of HUVECs in Boyden cham-
ber experiment (*125 pg/ml P  0.05, n  8). D:
sFRP4 inhibited ring formation by HUVECs.
Fewer rings were counted in sFRP4 sets than that
of control (*125 pg/ml P  0.05). E: Time-de-
pendent sFRP4 treatment destabilized the ring
structures in the endothelial layer. The black
arrows in the control group indicate rings. In
the sFRP4 treated group, the black arrow indi-
cates the breakdown of a ring structure, whereas
the white arrows show loss of sprouts and
pseudopodia. F: Comparative analysis of sFRP4
(125 pg/ml) and Avastin (125 pg/ml) actions on
wound healing with or without VEGF (20 nmol/
L). Both sFRP4 and Avastin blocked VEGF-de-
pendent wound healing, whereas sFRP4 is more
efficient than Avastin in blocking the VEGF-de-
pendent wound healing *P  0.01, n  6.
1510 Muley et al
AJP March 2010, Vol. 176, No. 3
sion of nuclear -catenin in HUVECs treated with sFRP4
(125 and 250 pg/ml). There were negligible levels of
nuclear -catenin protein detectable by Western blot
analysis after treatment with sFRP4 (see Supplemental
Figure S1 at http://ajp.amjpathol.org). We then examined
the effect of sFRP4 treatment on the Wnt signaling path-
way using HUVECs.
Wnt/-Catenin Pathway
The effect of sFRP4 on HUVECs after activation of the
Wnt/-catenin pathway was examined. LiCl is known to
block glycogen synthase kinase-3 (GSK-3), a down-
stream target for Wnt signaling, thereby increasing cel-
lular levels of -catenin.31 We found the addition of LiCl
(20 mmol/L) had no effect on HUVEC migration (Figure
2A), whereas sFRP4 produced a significant reduction in
cell migration (P  0.05). However, the addition of LiCl
promoted cell proliferation, but this effect was signifi-
cantly reduced after administration of sFRP4 (P  0.05;
Figure 2B). The data demonstrate that sFRP4 is able to
block Wnt signaling via the canonical -catenin pathway.
We also investigated whether sFRP4 was able to antag-
onize one or more other Wnt signaling pathways to exert
its inhibitory effects.
Wnt/Calcium Pathway
The impact of sFRP4 on the Wnt/calcium pathway was
examined using HUVECs. After administration of sFRP4
there was a steady time-dependent increase in intracel-
lular calcium levels. The resultant significant increase
(P  0.05) in intracellular calcium levels once steady
state was reached is shown in Figure 2C. Our findings
indicate that sFRP4 not only blocks the Wnt/-catenin
pathway but it also activates the Wnt/Calcium pathway.
Wnt/Planar Cell Polarity Pathway
Involvement of sFRP4 in the planar cell polarity/c-Jun
NH2-terminal kinase (JNK) pathway was also examined
using HUVECs. Western blot analysis demonstrated a
reduction in nuclear c-Jun protein expression after treat-
ment with 125 and 250 pg/ml sFRP4 (Figure 2D). There-
fore, our data demonstrate a regulatory role of sFRP4 in
all three Wnt signaling pathways.
Involvement of sFRP4 in Redox Activation
Reactive oxygen species (ROS), particularly H2O2, pro-
mote cell death in tumor models via a stress-induced
apoptotic pathway,32 whereas FoxO (a Forkhead tran-
scription factors class) antagonizes ROS effects.33 ROS
may perform a role in the antiangiogenic effects of sFRP4
through the -catenin–T-cell factor (Tcf) axis because
FoxO-mediated transcription requires binding of -cate-
nin.34 -catenin is required for the transcriptional activity
of the Tcf family of transcription factors, which are the
downstream effectors of the Wnt/-catenin pathway.9,35
The involvement of ROS as a possible effector pathway
for sFRP4 was investigated in vitro with EA.hy926 cells.
Incubation with sFRP4 increased levels of both superox-
ide and H2O2 (Figure 3, A and B), a consequence of
reduced levels of cellular catalase (Figure 3C), a free
radical scavenger essential for maintenance of normal
cell function. Administration of SOD, which can counter-
act the activation of the ROS pathway, resulted in resto-
ration of the inhibitory effect of sFRP4 on wound healing
(Figure 3D). These results indicate that sFRP4 is able to
activate ROS, most likely because of its ability to block
Wnt/-catenin interaction, thereby interfering with FoxO-
mediated transcription and, subsequently, Tcf activity.
Thus, sFRP4 clearly demonstrated antiangiogenic ef-
fects on endothelial cells in vitro, and subsequent inves-
tigations examined its potential as an angiogenesis inhib-
itor in vivo.
Investigation of sFRP4 Effects in an in Vivo
Environment
We examined the effect of recombinant sFRP4 on the
whole vascular bed of the developing embryo (day 3)
using a modified chicken chorioallantoic membrane as-
say.26 A significant reduction in vascularity was observed
in the area of sFRP4 application. This reduction of vas-
cularity is illustrated in Figure 4A, which comprises con-
Figure 2. Analysis of sFRP4-Wnt signaling pathway interaction in vitro.
A: sFRP4 blocked endothelial cell migration. HUVECs treated with LiCl had
no effect on migration, whereas there was a significant reduction in migration
after sFRP4 treatment, even in the presence of LiCl (*P  0.05, n  3).
B: HUVECs treated with a combination of LiCl and sFRP4 showed a lower cell
proliferation index than that of LiCl-treated cells (*LiCl P  0.05;
**sFRP4LiCl P  0.05, n  3). C: Exposure of HUVECs to sFRP4 is
associated with a significant increase in intracellular Ca2 (*125 pg/ml P 
0.05; *250 pg/ml P  0.05. Control n  4, sFRP4 n  7). D: Exposure of
HUVECs to sFRP4 resulted in a decrease in nuclear c-Jun levels. -actin was
used as loading control. Results of Western blot analysis for c-Jun (dissected
from the gel) are shown beneath the graph (125 pg/ml P  0.1; *250 pg/ml
P  0.01, n  3).
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trol and sFRP4 treated groups at 0, 6, and 12 hours
posttreatment, together with their corresponding mean
vessel lengths.
Vessel formation and the effect of sFRP4 were exam-
ined using three in vivo assays (cotton plug, Matrigel
sponge, and Matrigel plug implants). After sFRP4 treat-
ment, all groups showed a significant decrease in the
amount of hemoglobin (Figure 4B), indicating a reduction
in vascularization from control levels. The number of junc-
tions (branch points) was also quantified, with all treat-
ment groups showing a significant reduction (Figure 4C).
Finally, the effect of sFRP4 on the growth of an estab-
lished aggressive tumor was then examined using a mu-
rine tumor model. SKOV-3 cells, an aggressive human
tumor cell line derived from ovarian serous cystadeno-
carcinoma, were implanted subcutaneously into BALB/c
nude mice. Strikingly, over a treatment period of 3 weeks,
the efficacy of sFRP4 to inhibit angiogenesis mimicked
the effects of the VEGF-blocking antibody Avastin, a clin-
ically approved angiogenesis inhibitor (Figure 5, A and
B). Furthermore, endothelial cell numbers were signifi-
cantly reduced (P  0.05) in both sFRP4 and Avastin-
treated groups compared with the control (Figure 5C).
Microscopically, there was no evidence of cellular de-
generation among the tumor cells, however the cyto-
plasm within the SKOV cells in the treated groups (Avas-
tin and sFRP4) was enlarged and resembled cysts (see
Supplemental Figure S2 at http://ajp.amjpathol.org).
Treatment with sFRP4 or Avastin did not result in any
evidence of systemic toxicity or adverse effects as illus-
trated by unchanged animal behavior, bodyweight, or
macroscopic appearance of the liver or kidney at nec-
ropsy. Liver and kidney samples examined using light
microscopy showed no adverse effects of treatment (see
Supplemental Figure S3 at http://ajp.amjpathol.org).
sFRP4 and Avastin treated tumors showed few apo-
ptotic events that did not differ from control levels, as
determined using TUNEL assay (Figure 5D). The few
sites of apoptotic activity were localized to the endothe-
lium of sFRP4 and Avastin-treated tumors (Figure 5E).
This observation, together with strong in vitro evidence,
suggests that sFRP4 acts on tumor blood vessels and
thus indirectly restricts tumor growth. To test this hypoth-
esis, HUVECs and SKOV-3 cells were exposed to sFRP4
in vitro for 24 hours and, using a JC-1 assay, we observed
that sFRP4 induced apoptosis in HUVECs (Figure 5F). In
contrast, SKOV-3 cells exhibited no change in viability,
suggesting that sFRP4 indeed predominantly inhibits an-
giogenesis by selectively targeting EC.
Discussion
Although the sFRPs are normally associated with antag-
onism of the Wnt signaling pathway, depending on their
concentration, they may promote Wnt activity.12 Our data
demonstrate a steady increase in intracellular calcium
levels after sFRP4 treatment, and it has been shown that
such a prolonged but low increase in total intracellular
Figure 3. Involvement of sFRP4 in redox activation. A: sFRP4 treatment
enhanced superoxide generation in sFRP4-treated cells (*125 pg/ml P 0.05,
n  3). B: sFRP4 increased hydrogen peroxide formation. The level of
hydrogen peroxide in 125 pg/ml sFRP4-treated cells was increased compared
with control (*125 pg/ml P  0.05, n  3). C: The catalase activity decreased
in sFRP4-treated cells in a time-dependent manner (*125 pg/ml P  0.05,
n  3). D: The addition of superoxide dismutase (SOD; 150 SI units) was
able to restore the effect of sFRP4 on wound healing (*125 pg/ml P  0.01,
n  3). EA.hy926 cells were used for these studies. Figure 4. Effect of sFRP4 on ex vivo and in vivo angiogenesis. A: It is evident
from the representative images and graph that angiogenesis was blocked by
sFRP4 treatment. (*125 pg/ml P  0.05, n  3). B: sFRP4 restricts in vivo
angiogenesis. sFRP4 treated implants contained less hemoglobin than control
implants (*125 pg/ml P  0.05, n  3), indicating a reduction in numbers of
angiogenic vessels. C: Quantitation of vessel junctions for each implant
demonstrating significantly fewer vessels (*125 pg/ml P  0.05, n  3) after
sFRP4 treatment.
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calcium leads to activation of calcineurin.36 Recently,
sFRP2 has been shown to stimulate the Wnt/Ca2 path-
way by the dephosphorylation of cytoplasmic nuclear
factor associated with T cells (NFAT) by calcineurin, lead-
ing to translocation of NFAT into the nucleus where it acts
as a transcription factor.37 This may explain the ability of
sFRP4 to activate the Wnt/Ca2 pathway in our studies.
LiCl has been shown to block the activation of GSK3-,
thereby increasing cytoplasmic -catenin levels and al-
lowing -catenin translocation to the nucleus. In the nu-
cleus it can bind to transcription factors of the T-cell
factor/lymphocyte enhancing factor family (Tcf/Lef) and
upregulate genes associated with angiogenesis such as
the matrix metalloproteinase 7 and the extracellular ma-
trix component fibronectin; as well as genes associated
with migration and proliferation such as cyclin D1, c-myc,
cyclooxygenase-2, and VEGF.38 A recent report has dem-
onstrated that, in mice, Wnt7a and Wnt7b are required for
normal angiogenesis in the brain and that blockade of
Wnt/-catenin also disrupts angiogenesis in the develop-
ing mouse brain.39
We have demonstrated that sFRP4 suppresses the
translocation of -catenin into the nucleus of HUVECs to
adversely affect EC functions (see Supplemental Figure
S1 at http://ajp.amjpathol.org). Furthermore, the ability of
sFRP4 to antagonize the Wnt/Planar Cell Polarity pathway
by reducing nuclear c-Jun expression has a synergistic
effect on reducing EC functions because JNK is required
for -catenin nuclear localization.40 The ability for sFRP4
to antagonize both the canonical -catenin and nonca-
nonical c-JNK pathways is in accordance with a previous
study, which reported that sFRP4 antagonized Wnt7a
signaling via both the canonical -catenin and nonca-
nonical c-JNK pathways in endometrial cancer cells.41
Therefore, sFRP4 exhibits a multilevel effect on -cate-
nin. It directly antagonizes the canonical Wnt/-catenin
pathway and also the noncanonical Wnt/planar cell po-
larity pathway. Additionally, its activation of the Wnt/Ca2
pathway has an indirect effect in that it can antagonize
the Wnt/-catenin pathway.42–46 Furthermore, reduc-
tion of -catenin correlates with EC apoptosis.47,48 Our
data are in accordance with earlier findings, which
reported that Wnt/-catenin signaling is involved in the
regulation of EC migration and cell cycle progres-
sion.49 Based on our findings we have proposed a
model through which sFRP4 interacts with the Wnt
signaling pathway (Figure 6).
It has recently been reported that bone morphogenetic
protein 2 (BMP-2) can induce angiogenesis in human
PAECs by activating both Wnt/-catenin and Wnt/PCP
signaling pathways.22 It is interesting to observe that
pro-angiogenic (BMP-2) and antiangiogenic (sFRP4) pro-
teins use the same Wnt signaling pathways to exert their
effects.
Our investigations into the effect of sFRP4 on ROS
demonstrated a significant increase in the generation of
superoxide and H2O2. It has been shown that increased
cellular oxidative stress (exemplified by H2O2) relocalizes
FOXO to the nucleus where it promotes the association of
FOXOs with -catenin and competes with the binding of
Figure 5. Inhibitory effect of sFRP4 on SKOV tumors. A: Over a treatment period of 3 weeks the efficacy of sFRP4 mimicked the effects of the VEGF-blocking
antibody Avastin. B: Photographs of the gross morphology of the tumors highlighting the differences in size. C: In vivo quantification of EC numbers per field
of view in tumors from PBS, sFRP4 (100 g/100 l), and Avastin (125 g/100 l) groups showing a significant reduction in EC numbers (as determined by CD31
staining) in the treated groups (*P 0.05, n 6). D: The percentage of apoptotic endothelial cells counted per field of view did not vary between treatment groups
(n  6). E: Microscopy showing results of a TUNEL assay for each treatment group (125pg/ml). Arrows indicate endothelial cells undergoing apoptosis. Scale
bar  50 m. F: In vitro evaluation of apoptosis using JC-1 assay clearly demonstrating a significant increase (*P  0.05, n  3) in apoptosis in HUVECs, whereas
SKOV cells remained unaffected.
sFRP4: An Angiogenesis Inhibitor 1513
AJP March 2010, Vol. 176, No. 3
-catenin to Tcf. H2O2 promotes FOXO-mediated tran-
scription at the expense of -catenin/Tcf–mediated tran-
scription.50,51 Nitric Oxide (NO) synthesized by endothe-
lial NO synthase (eNOS) is essential for EC survival,
migration, and postnatal neovascularization. The tran-
scriptional repression of eNOS by FOXOs might also
contribute to the antiangiogenic effects of FOXOs on EC.
In addition, changes in expression of several extracellular
matrix proteins, such as collagen and matrix metallopro-
teinases, indicate that FOXOs might also be involved in
regulating vessel remodeling.52 Our data demonstrated
that sFRP4 facilitates the selective apoptosis of endothe-
lial cells in vitro (Figure 5F) and this may, in part, be
related to the activation of cellular reactive oxygen spe-
cies, which then facilitate nuclear entry of FOXO (which
preferentially binds to the limited pool of nuclear -cate-
nin), thus driving the cell toward apoptosis. A proposed
model for the interaction between ROS and Wnt (through
its action on nuclear -catenin) is shown in Figure 7.
Our examination of a possible interaction between
sFRP4 and VEGF found that the application of exogenous
VEGF was unable to block the effects of sFRP4 on cell
migration. A relationship between VEGF and the Wnt
pathway has been reported previously,53 and the authors
reported that VEGF induced EC migration and prolifera-
tion through tyrosine phosphorylation of -catenin that
was dependant on protein kinase C. Recently the Wnt/-
catenin pathway has been reported to regulate VEGF-A
gene transcription.54 Our in vitro results indicate that
sFRP4 inhibits EC migration and proliferation by blocking
-catenin entry into the nucleus, thereby preventing tran-
scription of angiogenesis associated genes (eg, VEGF).
The non-canonical Wnt5a signaling pathway has been
recently demonstrated to induce proliferation and sur-
vival of ECs while up-regulating matrix metalloprotein-
ase-1 expression in ECs.5 The primary step in angiogen-
esis involves breakdown of the extracellular matrix,55 and
our in vitro data demonstrate that sFRP4 prevents forma-
tion of pseudopodia, EC ring formation, and disruption of
ring structures in EC via its effects on both canonical and
noncanonical Wnt signaling pathways by reducing nu-
clear entry of -catenin. In addition, the activation of ROS
by sFRP4 also reduces the nuclear levels of -catenin.
The net result is that sFRP4 not only reduces migration
and proliferation of ECs, but also drives ECs toward
apoptosis and, thereby, inhibits angiogenesis.
Examination of the effects of sFRP4 in an in vivo envi-
ronment demonstrated that sFRP4 can significantly re-
duce the development of blood vessels in both the
physiological setting (chicken chorioallantoic membrane
assay) and wound healing response (cotton plug and
matrigel implants). Furthermore, we were able to demon-
strate that sFRP4 can halt the growth of the aggressive
SKOV-3 ovarian tumor via its antiangiogenic properties
without affecting tumor cell viability, a finding similar to
earlier studies.17,18 VEGF is produced by SKOV-3 cells56
and can increase vessel permeability, thereby facilitating
tumor growth by aiding the passage of macromolecules
and growth factors directly into the tumor environment.
Furthermore, VEGF promotes endothelial cell survival,57
and together these VEGF-induced effects may act to
counter sFRP4 inhibition of angiogenesis but are insufficient
to support further tumor growth. Thus, sFRP4 treatment
resulted in developmental stasis of the tumor. Surprisingly,
our in vivo tumor data demonstrated no appreciable differ-
ence in numbers of apoptotic ECs among all treatment
groups. However, in previous research, TUNEL-positive
ECs were detected with very low frequency, which did not
correspond with the dramatic loss of capillarization present
in the regressing corpus luteum (approximately 1 in 100
apoptotic cells).58 The authors discovered this phenome-
non was attributable to a combination of rounding and
subsequent detachment of ECs from the basement mem-
brane together with contractive occlusion of blood vessels.
Hence, it is not surprising that, because of the speed of the
apoptotic process, ECs can be rapidly dispersed into the
blood stream in vivo and avoid being detected using apo-
ptosis assays.
Our in vivo data also highlight the endothelial-specific
action of sFRP4 observed as a significant reduction in the
number of ECs within the tumor mass. This finding is com-
parable with the antiangiogenic properties demonstrated
by Avastin in selectively reducing the number of ECs.59
In summary, these studies demonstrate a previously
unknown role of sFRP4 as an inhibitor of angiogenesis
and illustrate sFRP4 inhibition of blood vessel formation
Figure 6. Interaction between sFRP4 and the Wnt signaling pathway. sFRP4
antagonizes the Wnt/-catenin and Wnt/PCP pathways while activating the
Wnt/Ca2 pathway, the net result being a reduction in translocation of
-catenin to the nucleus. As a consequence, there is diminished -catenin–
Tcf interaction, resulting in a reduction in the transcription of angiogenesis
genes.
Figure 7. Interaction between sFRP4 and ROS. sFRP4 increases intracellular
ROS, which drives FOXO translocation into the nucleus where it preferen-
tially binds to -catenin, thereby promoting cell apoptosis while simulta-
neously blocking -catenin–Tcf interaction, which results in down-regulation
of angiogenesis-associated genes.
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both in vitro and in vivo. This unique antiangiogenic effect
of sFRP4 affects the Wnt/-catenin and PCP signaling
pathways to inhibit the accumulation of -catenin in the
nucleus of endothelial cells. As a consequence, sFRP4
inhibits the migration and proliferation of endothelial cells,
both crucial steps in angiogenesis. In addition, sFRP4 is
able to increase levels of ROS in ECs, thereby promoting
EC apoptosis. Thus, our data promote sFRP4 as a potent
angiogenesis inhibitor, which has therapeutic potential
for the control of angiogenesis-dependent pathologies.
Acknowledgments
We thank Vijay Shah (GI Research Unit, Mayo Clinic, Roches-
ter, MN) for the ECV-304 cells, Cora-Jean Edgel (Tissue
Culture Facility, UNC Lineburger Comprehensive Cancer
Center, University of North Carolina, Chapel Hill) for the Li
EA.hy926 cells Robert Rieben (University of Bern, Switzer-
land) for the PAECs and Dr. Chooi-May Lai (Lions Eye
Institute, The University of Western Australia) for the
HUVECs. We thank Robert Friis (University of Bern, Switzer-
land) for his scientific advice. We also thank Mary Lee,
Leonie Khoo, Guy Ben-Ary, Maike Bollen, Greg Cozens,
Uttara Saran, Simon Mahoney, David Longman, and Ber-
nadette Pedersen (School of Anatomy and Human Biology,
The University of Western Australia) for their technical as-
sistance and Simon Handford (Office of Industry and Inno-
vation, The University of Western Australia) for his support
and help with the patent application and commercialization
of this protein.
References
1. Nusse R, Varmus HE: Wnt genes. Cell 1992, 69:1073–1087
2. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT,
Morin PJ, Vogelstein B, Kinzler KW: Identification of c-MYC as a target
of the APC pathway. Science 1998, 281:1509–1512
3. Hsieh JC, Rattner A, Smallwood PM, Nathans J: Biochemical charac-
terization of Wnt-frizzled interactions using a soluble, biologically
active vertebrate Wnt protein. Proc Natl Acad Sci USA 1999,
96:3546–3551
4. Finch PW, He X, Kelley MJ, Uren A, Schaudies RP, Popescu NC,
Rudikoff S, Aaronson SA, Varmus HE, Rubin JS: Purification and
molecular cloning of a secreted, Frizzled-related antagonist of Wnt
action. Proc Natl Acad Sci USA 1997, 94:6770–6775
5. Masckauchan TN, Agalliu D, Vorontchikhina M, Ahn A, Parmalee NL,
Li CM, Khoo A, Tycko B, Brown AM, Kitajewski J: Wnt5a signaling
induces proliferation and survival of endothelial cells in vitro and
expression of MMP-1 and Tie-2. Mol Biol Cell 2006, 17:5163–5172
6. Goodwin AM, Kitajewski J, D’Amore PA: Wnt1 and Wnt5a affect
endothelial proliferation and capillary length; Wnt2 does not. Growth
Factors 2007, 25:25–32
7. Uren A, Reichsman F, Anest V, Taylor WG, Muraiso K, Bottaro DP,
Cumberledge S, Rubin JS: Secreted frizzled-related protein-1 binds
directly to Wingless and is a biphasic modulator of Wnt signaling.
J Biol Chem 2000, 275:4374–4382
8. Bafico A, Gazit A, Pramila T, Finch PW, Yaniv A, Aaronson SA:
Interaction of frizzled related protein (FRP) with Wnt ligands and the
frizzled receptor suggests alternative mechanisms for FRP inhibition
of Wnt signaling. J Biol Chem 1999, 274:16180–16187
9. Moon RT, Bowerman B, Boutros M, Perrimon N: The promise and perils
of Wnt signaling through beta-catenin. Science 2002, 296:1644–1646
10. Reya T, Clevers H: Wnt signalling in stem cells and cancer. Nature
2005, 434:843–850
11. Turashvili G, Bouchal J, Burkadze G, Kolar Z: Wnt signaling pathway
in mammary gland development and carcinogenesis. Pathobiology
2006, 73:213–223
12. Kawano Y, Kypta R: Secreted antagonists of the Wnt signalling path-
way. J Cell Sci 2003, 116:2627–2634
13. White L, Suganthini G, Friis R, Dharmarajan A, Charles A: Expression
of secreted frizzled-related protein 4 in the primate placenta. Reprod
Biomed Online 2009, 18:104–110
14. Constantinou T, Baumann F, Lacher MD, Saurer S, Friis R, Dharmarajan
A: SFRP-4 abrogates Wnt-3a-induced beta-catenin and Akt/PKB signal-
ling and reverses a Wnt-3a-imposed inhibition of in vitro mammary
differentiation. J Mol Signal 2008, 3:10–23
15. Drake JM, Friis RR, Dharmarajan AM: The role of sFRP4, a secreted
frizzled-related protein, in ovulation. Apoptosis 2003, 8:389–397
16. Hsieh M, Mulders SM, Friis RR, Dharmarajan A, Richards JS: Expres-
sion and localization of secreted frizzled-related protein-4 in the
rodent ovary: evidence for selective up-regulation in luteinized gran-
ulosa cells. Endocrinology 2003, 144:4597–4606
17. Fox S, Dharmarajan A: WNT signaling in malignant mesothelioma.
Front Biosci 2006, 11:2106–2112
18. Feng Han Q, Zhao W, Bentel J, Shearwood AM, Zeps N, Joseph D,
Iacopetta B, Dharmarajan A: Expression of sFRP-4 and beta-catenin
in human colorectal carcinoma. Cancer Lett 2006, 231:129–137
19. Wang H, Gilner JB, Bautch VL, Wang DZ, Wainwright BJ, Kirby SL,
Patterson C: Wnt2 coordinates the commitment of mesoderm to he-
matopoietic, endothelial, and cardiac lineages in embryoid bodies.
J Biol Chem 2007, 282:782–791
20. Dufourcq P, Couffinhal T, Ezan J, Barandon L, Moreau C, Daret D,
Duplaa C: FrzA, a secreted frizzled related protein, induced angio-
genic response. Circulation 2002, 106:3097–3103
21. Goodwin AM, Sullivan KM, D’Amore PA: Cultured endothelial cells
display endogenous activation of the canonical Wnt signaling path-
way and express multiple ligands, receptors, and secreted modula-
tors of Wnt signaling. Dev Dyn 2006, 235:3110–3120
22. de Jesus Perez VA, Alastalo TP, Wu JC, Axelrod JD, Cooke JP,
Amieva M, Rabinovitch M: Bone morphogenetic protein 2 induces
pulmonary angiogenesis via Wnt-beta-catenin and Wnt-RhoA-Rac1
pathways. J Cell Biol 2009, 184:83–99
23. Viola HM, Arthur PG, Hool LC: Transient exposure to hydrogen per-
oxide causes an increase in mitochondria-derived superoxide as a
result of sustained alteration in L-type Ca2 channel function in the
absence of apoptosis in ventricular myocytes. Circ Res 2007,
100:1036–1044
24. Bradford MM: A rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye
binding. Anal Biochem 1976, 72:248–254
25. Chopra M, Dharmarajan AM, Meiss G, Schrenk D: Inhibition of UV-C
light-induced apoptosis in liver cells by 2,3,7,8-tetrachlorodibenzo-p-
dioxin. Toxicol Sci 2009, 111:49–63
26. Auerbach R, Lewis R, Shinners B, Kubai L, Akhtar N: Angiogenesis
assays: a critical overview. Clin Chem 2003, 49:32–40
27. Niemisto A, Dunmire V, Yli-Harja O, Zhang W, Shmulevich I: Robust
quantification of in vitro angiogenesis through image analysis. IEEE
Trans Med Imaging 2005, 24:549–553
28. Berg MN, Dharmarajan AM, Waddell BJ: Glucocorticoids and pro-
gesterone prevent apoptosis in the lactating rat mammary gland.
Endocrinology 2002, 143:222–227
29. White L, Dharmarajan A, Charles A: Caspase-14: a new player in cy-
totrophoblast differentiation. Reprod Biomed Online 2007, 14:300–307
30. Smiley ST, Reers M, Mottola-Hartshorn C, Lin M, Chen A, Smith TW,
Steele GD Jr, Chen LB: Intracellular heterogeneity in mitochondrial
membrane potentials revealed by a J-aggregate-forming lipophilic
cation JC-1. Proc Natl Acad Sci USA 1991, 88:3671–3675
31. Clement-Lacroix P, Ai M, Morvan F, Roman-Roman S, Vayssiere B,
Belleville C, Estrera K, Warman ML, Baron R, Rawadi G: Lrp5-inde-
pendent activation of Wnt signaling by lithium chloride increases
bone formation and bone mass in mice. Proc Natl Acad Sci USA
2005, 102:17406–17411
32. Banhegyi G, Benedetti A, Csala M, Mandl J: Stress on redox. FEBS
Lett 2007, 581:3634–3640
33. Burgering BM, Medema RH: Decisions on life and death: fOXO
Forkhead transcription factors are in command when PKB/Akt is off
duty. J Leukoc Biol 2003, 73:689–701
34. Essers MA, de Vries-Smits LM, Barker N, Polderman PE, Burgering
sFRP4: An Angiogenesis Inhibitor 1515
AJP March 2010, Vol. 176, No. 3
BM, Korswagen HC: Functional interaction between beta-catenin and
FOXO in oxidative stress signaling. Science 2005, 308:1181–1184
35. Staal FJ, Clevers H: Tcf/Lef transcription factors during T-cell
development: unique and overlapping functions, Hematol J 2000,
1:3–6
36. Pandur P, Maurus D, Kuhl M: Increasingly complex: new players
enter the Wnt signaling network. Bioessays 2002, 24:881–884
37. Courtwright A, Siamakpour-Reihani S, Arbiser JL, Banet N, Hilliard E,
Fried L, Livasy C, Ketelsen D, Nepal DB, Perou CM, Patterson C,
Klauber-Demore N: Secreted frizzle-related protein 2 stimulates an-
giogenesis via a calcineurin/NFAT signaling pathway. Cancer Res
2009, 69:4621–4628
38. Goodwin AM, D’Amore PA: Wnt signaling in the vasculature. Angio-
genesis 2002, 5:1–9
39. Daneman R, Agalliu D, Zhou L, Kuhnert F, Kuo CJ, Barres BA:
Wnt/beta-catenin signaling is required for CNS, but not non-CNS,
angiogenesis, Proc Natl Acad Sci USA 2009, 106:641–646
40. Phelps RA, Chidester S, Dehghanizadeh S, Phelps J, Sandoval IT, Rai
K, Broadbent T, Sarkar S, Burt RW, Jones DA: A two-step model for
colon adenoma initiation and progression caused by APC loss. Cell
2009, 137:623–634
41. Carmon KS, Loose DS: Secreted frizzled-related protein 4 regulates
two Wnt7a signaling pathways and inhibits proliferation in endome-
trial cancer cells. Mol Cancer Res 2008, 6:1017–1028
42. Schneider I, Houston DW, Rebagliati MR, Slusarski DC: Calcium
fluxes in dorsal forerunner cells antagonize beta-catenin and alter
left-right patterning. Development 2008, 135:75–84
43. Topol L, Jiang X, Choi H, Garrett-Beal L, Carolan PJ, Yang Y: Wnt-5a
inhibits the canonical Wnt pathway by promoting GSK-3-independent
beta-catenin degradation. J Cell Biol 2003, 162:899–908
44. Ishitani T, Kishida S, Hyodo-Miura J, Ueno N, Yasuda J, Waterman M,
Shibuya H, Moon RT, Ninomiya-Tsuji J, Matsumoto K: The TAK1-NLK
mitogen-activated protein kinase cascade functions in the Wnt-5a/
Ca(2) pathway to antagonize Wnt/beta-catenin signaling. Mol Cell
Biol 2003, 23:131–139
45. Westfall TA, Brimeyer R, Twedt J, Gladon J, Olberding A, Furutani-
Seiki M, Slusarski DC: Wnt-5/pipetail functions in vertebrate axis
formation as a negative regulator of Wnt/beta-catenin activity. J Cell
Biol 2003, 162:889–898
46. Torres MA, Yang-Snyder JA, Purcell SM, DeMarais AA, McGrew LL,
Moon RT: Activities of the Wnt-1 class of secreted signaling factors are
antagonized by the Wnt-5A class and by a dominant negative cadherin
in early Xenopus development. J Cell Biol 1996, 133:1123–1137
47. Klein D, Demory A, Peyre F, Kroll J, Geraud C, Ohnesorge N,
Schledzewski K, Arnold B, Goerdt S: Wnt2 acts as an angiogenic
growth factor for non-sinusoidal endothelial cells and inhibits expres-
sion of stanniocalcin-1. Angiogenesis 2009, 12:251–265
48. Wu WB, Peng HC, Huang TF: Disintegrin causes proteolysis of beta-
catenin and apoptosis of endothelial cells. Involvement of cell-cell
and cell-ECM interactions in regulating cell viability. Exp Cell Res
2003, 286:115–127
49. Hanai J, Gloy J, Karumanchi SA, Kale S, Tang J, Hu G, Chan B,
Ramchandran R, Jha V, Sukhatme VP, Sokol S: Endostatin is a
potential inhibitor of Wnt signaling. J Cell Biol 2002, 158:529–539
50. Hoogeboom D, Essers MA, Polderman PE, Voets E, Smits LM,
Burgering BM: Interaction of FOXO with beta-catenin inhibits beta-cate-
nin/T cell factor activity. J Biol Chem 2008, 283:9224–9230
51. Almeida M, Han L, Martin-Millan M, O’Brien CA, Manolagas SC:
Oxidative stress antagonizes Wnt signaling in osteoblast precursors
by diverting beta-catenin from T cell factor- to forkhead box O-
mediated transcription. J Biol Chem 2007, 282:27298–27305
52. Potente M, Urbich C, Sasaki K, Hofmann WK, Heeschen C, Aicher A,
Kollipara R, DePinho RA, Zeiher AM, Dimmeler S: Involvement of Foxo
transcription factors in angiogenesis and postnatal neovasculariza-
tion. J Clin Invest 2005, 115:2382–2392
53. Cohen AW, Carbajal JM, Schaeffer RC Jr: VEGF stimulates tyrosine
phosphorylation of beta-catenin and small-pore endothelial barrier
dysfunction, Am J Physiol 1999, 277:H2038–H2049
54. Zhang X, Gaspard JP, Chung DC: Regulation of vascular endothelial
growth factor by the Wnt and K-ras pathways in colonic neoplasia.
Cancer Res 2001, 61:6050–6054
55. Giambernardi TA, Grant GM, Taylor GP, Hay RJ, Maher VM, McCormick
JJ, Klebe RJ: Overview of matrix metalloproteinase expression in cul-
tured human cells. Matrix Biol 1998, 16:483–496
56. Mesiano S, Ferrara N, Jaffe RB: Role of vascular endothelial growth
factor in ovarian cancer: inhibition of ascites formation by immuno-
neutralization. Am J Pathol 1998, 153:1249–1256
57. Nagy JA, Dvorak AM, Dvorak HF: VEGF-A and the induction of
pathological angiogenesis. Annu Rev Pathol 2007, 2:251–275
58. Modlich U, Kaup FJ, Augustin HG: Cyclic angiogenesis and blood
vessel regression in the ovary: blood vessel regression during lute-
olysis involves endothelial cell detachment and vessel occlusion. Lab
Invest 1996, 74:771–780
59. Kim TI, Kim SW, Kim S, Kim T, Kim EK: Inhibition of experimental
corneal neovascularization by using subconjunctival injection of be-
vacizumab (Avastin). Cornea 2008, 27:349–352
1516 Muley et al
AJP March 2010, Vol. 176, No. 3
